Non-small cell lung cancer: Clinical practice guidelines in oncology

Most patients with non–small cell lung cancer (NSCLC) are diagnosed with advanced cancer. These guidelines only include information about stage IV NSCLC. Patients with widespread metastatic disease (stage IV) are candidates for systemic therapy, clinical trials, and/or palliative treatment. The goal is to identify patients with metastatic disease before initiating aggressive treatment, thus sparing these patients from unnecessary futile treatment. If metastatic disease is discovered during surgery, then extensive surgery is often aborted. Decisions about treatment should be based on multidisciplinary discussion. (JNCCN 2012;10:1236–1271)

[1]  N Thatcher,et al.  A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Mehta,et al.  Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  R. Ginsberg,et al.  A prospective evaluation of magnetic resonance imaging, computed tomography, and mediastinoscopy in the preoperative assessment of mediastinal node status in bronchogenic carcinoma. , 1987, The Journal of thoracic and cardiovascular surgery.

[4]  J. Purdy,et al.  Evaluation of an objective plan-evaluation model in the three dimensional treatment of nonsmall cell lung cancer. , 1996, International journal of radiation oncology, biology, physics.

[5]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[6]  O. Chapet Complications aiguës et tardives des irradiations thoraciques , 2007 .

[7]  W. Curran,et al.  Lack of apparent difference in outcome between clinically staged IIIA and IIIB non-small-cell lung cancer treated with radiation therapy. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Cooper,et al.  Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. , 1982, The Journal of thoracic and cardiovascular surgery.

[9]  F. Fossella,et al.  A multicenter, randomized phase III study of docetaxel + cisplatin (DC) vs docetaxel + carboplatin (DCb) vs vinorelbine + cisplatin (VC) in chemotherapy-naive patients (Pts) with advanced and metastatic non-small cell lung cancer (NSCLC) , 2000 .

[10]  J S Lee,et al.  Clonal genetic alterations in the lungs of current and former smokers. , 1997, Journal of the National Cancer Institute.

[11]  J. Crowley,et al.  Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Crowley,et al.  Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  U. Francke,et al.  The structural gene for the M1 subunit of ribonucleotide reductase maps to chromosome 11, band p15, in human and to chromosome 7 in mouse. , 1988, Experimental cell research.

[14]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .

[15]  J. Lubin,et al.  Lung cancer and smoking cessation: patterns of risk. , 1993, Journal of the National Cancer Institute.

[16]  E. van Marck,et al.  Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. , 1997, The European respiratory journal.

[17]  R. Byhardt The evolution of Radiation Therapy Oncology Group (RTOG) protocols for nonsmall cell lung cancer. , 1995, International journal of radiation oncology, biology, physics.

[18]  M. Kris,et al.  Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  R. Ueda,et al.  Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. , 1989, Cancer research.

[21]  George Starkschall,et al.  Assessing respiration-induced tumor motion and internal target volume using four-dimensional computed tomography for radiotherapy of lung cancer. , 2007, International journal of radiation oncology, biology, physics.

[22]  W. Pao,et al.  Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[23]  T. Demmy,et al.  Discharge independence with minimally invasive lobectomy. , 2004, American journal of surgery.

[24]  R. Clough,et al.  Influence of tumor volume on survival in patients irradiated for non-small-cell lung cancer. , 2002, International journal of radiation oncology, biology, physics.

[25]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[26]  S. Baylin,et al.  v-Ha-ras oncogene insertion: a model for tumor progression of human small cell lung cancer. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Pignon,et al.  Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  X. Ducrocq,et al.  Induction chemotherapy does not increase the operative risk of pneumonectomy! , 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[29]  J. Contessa,et al.  ERBB receptor tyrosine kinases and cellular radiation responses , 2003, Oncogene.

[30]  J. Daurès,et al.  Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  B Van Duyse,et al.  Non-coplanar beam intensity modulation allows large dose escalation in stage III lung cancer. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  Ugo Pastorino,et al.  Computed tomography screening and lung cancer outcomes. , 2007, JAMA.

[33]  W. Curran,et al.  Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group , 2000 .

[34]  P. Pairolero,et al.  The significance of a cytologically negative pleural effusion in bronchogenic carcinoma. , 1978, Chest.

[35]  S Lippman,et al.  Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Arriagada,et al.  Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. , 1991, Journal of the National Cancer Institute.

[37]  H. Wagner Rational integration of radiation and chemotherapy in patients with unresectable stage IIIA or IIIB NSCLC. Results from the Lung Cancer Study Group, Eastern Cooperative Oncology Group, and Radiation Therapy Oncology Group. , 1993, Chest.

[38]  R. Arriagada,et al.  A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma , 1999, Cancer.

[39]  M. Decramer,et al.  Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. A study of 569 patients. , 1994, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[40]  R. Stephens,et al.  Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome , 2000, British Journal of Cancer.

[41]  J. Rosenman,et al.  Significant underdosing of small tumors or portions of tumor in lung cancer treatment , 2002 .

[42]  K E Stanley,et al.  Prognostic factors for survival in patients with inoperable lung cancer. , 1980, Journal of the National Cancer Institute.

[43]  Randall K Ten Haken,et al.  Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. , 2006, International journal of radiation oncology, biology, physics.

[44]  G. Raviv,et al.  Surgical treatment of solitary adrenal metastases from lung carcinoma , 1990, Journal of surgical oncology.

[45]  A. Marchevsky,et al.  Diagnosis of lung cancer by fibreoptic bronchoscopy: problems in the histological classification of non-small cell carcinomas. , 1984, Thorax.

[46]  R Mackie,et al.  A new approach to dose escalation in non-small-cell lung cancer. , 2001, International journal of radiation oncology, biology, physics.

[47]  C. Ling,et al.  Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[48]  K. Kerr,et al.  Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category , 2000, Journal of clinical pathology.

[49]  Lawrence B Marks,et al.  Dosimetric and clinical predictors for radiation-induced esophageal injury. , 2005, International journal of radiation oncology, biology, physics.

[50]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[51]  P. Hasleton,et al.  Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data , 2006, Histopathology.

[52]  E. Smit,et al.  An EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer , 2001 .

[53]  R. Malthaner,et al.  Number of lymph nodes harvested from a mediastinal lymphadenectomy: Results of the randomized, prospective ACOSOG Z0030 trial , 2007 .

[54]  R. Pazdur,et al.  Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  N. Anthonisen,et al.  Airways obstruction and the risk for lung cancer. , 1987, Annals of internal medicine.

[56]  Kemp Kernstine,et al.  Video-Assisted Thoracic Surgery in Lung Cancer Resection , 2007, Innovations.

[57]  Anthony J Alberg,et al.  Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.

[58]  Y. Bang,et al.  Optimization of Patient Selection for Gefitinib in Non–Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation , 2006, Clinical Cancer Research.

[59]  E. Constant,et al.  Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. , 1998 .

[60]  P Coy,et al.  The role of curative radiotherapy in the treatment of lung cancer , 1980, Cancer.

[61]  J. Mate,et al.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. , 1994, The New England journal of medicine.

[62]  B. Jeremic,et al.  Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  V. Budach,et al.  Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  M. Sporn,et al.  Autocrine secretion and malignant transformation of cells. , 1980, The New England journal of medicine.

[65]  Y. Takai,et al.  Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[66]  D. Zander,et al.  Immunohistochemistry for assessment of pulmonary and pleural neoplasms: a review and update. , 2008, International journal of clinical and experimental pathology.

[67]  N. Choi,et al.  Basis for new strategies in postoperative radiotherapy of bronchogenic carcinoma. , 1980, International journal of radiation oncology, biology, physics.

[68]  Diane D. Liu,et al.  The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma , 2002, Cancer.

[69]  M. Kris,et al.  Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens , 2000 .

[70]  P. Thomas,et al.  Cancer recurrence after resection: T1 N0 non-small cell lung cancer. Lung Cancer Study Group. , 1990, The Annals of thoracic surgery.

[71]  Stefano Monti,et al.  Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  G. Scagliotti,et al.  Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  M. Melamed,et al.  Multiple primary lung cancers. , 1975, The Journal of thoracic and cardiovascular surgery.

[74]  A. Gazdar,et al.  Lung cancer in never smokers — a different disease , 2007, Nature Reviews Cancer.

[75]  Atul C Mehta,et al.  Diagnosis of lung cancer: the guidelines. , 2003, Chest.

[76]  C. D. Wagter,et al.  Intensity-modulated radiotherapy in stage III non-small cell lung cancer: a planning study comparing 6 MV and 25 MV photons , 1998 .

[77]  K. Dickersin,et al.  Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma , 1998, Cancer.

[78]  David J Sugarbaker,et al.  Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  A. Curcio,et al.  Continuation of chemotherapy versus supportive care alone in patients with inoperable non‐small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study , 1989, Cancer.

[80]  D. Machin,et al.  A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. , 1992, British Journal of Cancer.

[81]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[82]  P. Bonomi,et al.  Neoadjuvant chemoradiation therapy in non-small cell lung cancer: the Rush University experience , 1993 .

[83]  P. Hoskin,et al.  482 Experience of a dose escalation study using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekendless) in non-small cell lung cancer , 1997 .

[84]  Jason Gong,et al.  Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial , 2006 .

[85]  R. Coleman,et al.  A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. , 2003, The Journal of thoracic and cardiovascular surgery.

[86]  J. Vansteenkiste FDG-PET for lymph node staging in NSCLC: a major step forward, but beware of the pitfalls. , 2005, Lung cancer.

[87]  S. Nakamura,et al.  Bronchial brushing and bronchial biopsy: comparison of diagnostic accuracy and cell typing reliability in lung cancer. , 1986, Thorax.

[88]  J. Crowley,et al.  Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. , 1993, The Journal of thoracic and cardiovascular surgery.

[89]  V. Lowe,et al.  Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. , 1995, Chest.

[90]  S. Rodenhuis,et al.  Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. , 1987, The New England journal of medicine.

[91]  N. Hanna,et al.  Survival update for the phase III study of pemetrexed vs docetaxel in non-small cell lung cancer (NSCLC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  J. Crowley,et al.  Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  R. Coleman,et al.  Serial Evaluation of Increased Chest Wall F-18 Fluorodeoxyglucose (FDG) Uptake Following Radiation Therapy in Patients With Bronchogenic Carcinoma. , 1998, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[94]  David Pérol,et al.  A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[95]  J C Rosenwald,et al.  Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. , 2000, International journal of radiation oncology, biology, physics.

[96]  T. Hashimoto,et al.  Hypofractionated high-dose proton beam therapy for stage I non-small-cell lung cancer: preliminary results of a phase I/II clinical study. , 2007, International journal of radiation oncology, biology, physics.

[97]  Steve B. Jiang,et al.  The management of respiratory motion in radiation oncology report of AAPM Task Group 76. , 2006, Medical physics.

[98]  J. Izbicki,et al.  Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis. , 1996, The Journal of thoracic and cardiovascular surgery.

[99]  Peter B Bach,et al.  Screening for lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.

[100]  E. Shaw,et al.  The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma , 1998, Cancer.

[101]  Brady T. West,et al.  High radiation dose may reduce the negative effect of large gross tumor volume in patients with medically inoperable early-stage non-small cell lung cancer. , 2007, International journal of radiation oncology, biology, physics.

[102]  J. Jett,et al.  Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small-cell lung cancer. , 2005, International journal of radiation oncology, biology, physics.

[103]  William Pao,et al.  Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus , 2007, Clinical Cancer Research.

[104]  Andrew Jackson,et al.  Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. , 2002, International journal of radiation oncology, biology, physics.

[105]  M T Munley,et al.  Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. , 2001, International journal of radiation oncology, biology, physics.

[106]  A. Jatoi,et al.  A Critical Look at the Role of Chemotherapy in Older Patients with Non-small Cell Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[107]  V. Rusch,et al.  Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  A. Marchetti,et al.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[110]  Julio Astudillo,et al.  Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. , 2006, The Lancet. Oncology.

[111]  M. Suntharalingam,et al.  The management of the patient undergoing combined modality therapy for locally advanced non-small cell lung cancer , 2003, Current treatment options in oncology.

[112]  N. Goldstein,et al.  Mucinous and nonmucinous bronchioloalveolar adenocarcinomas have distinct staining patterns with thyroid transcription factor and cytokeratin 20 antibodies. , 2001, American journal of clinical pathology.

[113]  D. Gandara,et al.  Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[114]  P. Marino,et al.  Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta‐analysis , 1996, Cancer.

[115]  I. Wistuba,et al.  Lung cancer preneoplasia. , 2006, Annual review of pathology.

[116]  D. Harpole,et al.  Pulmonary segmentectomy by thoracotomy or thoracoscopy: reduced hospital length of stay with a minimally-invasive approach. , 2007, The Annals of thoracic surgery.

[117]  Paolo Vineis,et al.  International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways. , 2008, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[118]  K. Ulm,et al.  Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[119]  J. Chang,et al.  Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers. , 2008, International journal of radiation oncology, biology, physics.

[120]  Feng Li,et al.  Mass screening for lung cancer with mobile spiral computed tomography scanner , 1998, The Lancet.

[121]  M. Kris,et al.  Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  R K Ten Haken,et al.  Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  M. Ladanyi,et al.  Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method , 2007, Clinical Cancer Research.

[124]  M. I. Saunders,et al.  Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: an interim report. CHART Steering Committee. , 1996, British Journal of Cancer.

[125]  B J Flehinger,et al.  Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. , 1984, Chest.

[126]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[127]  F. Sebag,et al.  VATS is an adequate oncological operation for stage I non-small cell lung cancer. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[128]  Elisabeth Brambilla,et al.  DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. , 2006, The New England journal of medicine.

[129]  Sasa Mutic,et al.  Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[130]  N. Green,et al.  Postresection irradiation for primary lung cancer. , 1975, Radiology.

[131]  J. Crowley,et al.  Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[132]  R. Wilson,et al.  Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[133]  C. Perez,et al.  Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non‐oat cell carcinoma of the lung. Report by the radiation therapy oncology group , 1982, Cancer.

[134]  P. Jänne,et al.  Bronchioloalveolar carcinoma: A Review of the Epidemiology, Pathology, and Treatment , 2005, Seminars in respiratory and critical care medicine.

[135]  K. Rosenzweig,et al.  Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. , 2001, International journal of radiation oncology, biology, physics.

[136]  J. Herndon,et al.  Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. , 1996, Journal of the National Cancer Institute.

[137]  W. Travis,et al.  The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. , 1994, American journal of clinical pathology.

[138]  J. Verschakelen,et al.  Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer , 2007, European Respiratory Journal.

[139]  Philip H. Gutin,et al.  Intensity-modulated Stereotactic Radiotherapy of Paraspinal Tumors: A Preliminary Report , 2004, Neurosurgery.

[140]  S. Swanson,et al.  Video-assisted thoracic surgery (VATS) resection for lung cancer. , 2002, The Surgical clinics of North America.

[141]  M. Allen Multiple benign lung tumors. , 2003, Seminars in thoracic and cardiovascular surgery.

[142]  Alona Muzikansky,et al.  First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[143]  L. Crinò,et al.  Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[144]  G. Omenn Chemoprevention of lung cancer: the rise and demise of beta-carotene. , 1998, Annual review of public health.

[145]  J. Ramsay,et al.  The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. , 1995, Chest.

[146]  E. Bergstralh,et al.  Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. , 1984, The Annals of thoracic surgery.

[147]  J. Crowley,et al.  Japan-SWOG common arm analysis of paclitaxel/carboplatin in advanced stage non-small cell lung cancer (NSCLC): A model for prospective comparison of cooperative group trials , 2004 .

[148]  F. Shepherd,et al.  Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[149]  D. Girling,et al.  Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. , 1996, Clinical oncology (Royal College of Radiologists (Great Britain)).

[150]  R. Arriagada,et al.  Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients , 1995 .

[151]  C. R. Kersh,et al.  Curative radiotherapy in non-small cell carcinoma of the lung. , 1990, International journal of radiation oncology, biology, physics.

[152]  R. Muschel,et al.  The molecular regulation of apoptosis and implications for radiation oncology. , 1997, International journal of radiation biology.

[153]  R. Ozols,et al.  Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  K. Eguchi,et al.  Phase II study of UFT in patients with advanced non-small cell lung cancer. , 1986, Japanese journal of clinical oncology.

[155]  A. Kirschbaum,et al.  Sublobar resections in stage IA non-small cell lung cancer: segmentectomies result in significantly better cancer-related survival than wedge resections. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[156]  A. J. Robertson,et al.  Observer variability in histopathological reporting of non-small cell lung carcinoma on bronchial biopsy specimens. , 1996, Journal of clinical pathology.

[157]  Stephanie Frost,et al.  Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. , 2003, Chest.

[158]  F. Stanzel,et al.  Fluorescent bronchoscopy: contribution for lung cancer screening? , 2004, Lung cancer.

[159]  S. Barni,et al.  Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[160]  H. Wagner Just enough palliation: radiation dose and outcome in patients with non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[161]  Evaluation and definitive management of medically inoperable early stage non-small-cell lung cancer. Part 2: newer treatment modalities. , 2006, Oncology.

[162]  D. Carbone,et al.  The molecular genetics of lung cancer. , 2008, Advances in internal medicine.

[163]  Kenneth E Rosenzweig,et al.  Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who's at risk? , 2008, International journal of radiation oncology, biology, physics.

[164]  S. Hassenbusch,et al.  Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis , 2006, Cancer.

[165]  D. Schottenfeld,et al.  Declining FEV1 and chronic productive cough in cigarette smokers: a 25-year prospective study of lung cancer incidence in Tecumseh, Michigan. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[166]  M. Anscher The irreversibility of radiation-induced fibrosis: fact or folklore? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[167]  S. L. Taylor,et al.  Simultaneous chemotherapy-radiotherapy with prophylactic cranial irradiation for inoperable adeno and large cell lung carcinoma: a Southwest Oncology Group Study. , 1984, International journal of radiation oncology, biology, physics.

[168]  K. Mori,et al.  Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI. , 1999, Chest.

[169]  J. Herndon,et al.  Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[170]  M Paesmans,et al.  Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[171]  Jeffrey Bradley,et al.  Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma. , 2005, International journal of radiation oncology, biology, physics.

[172]  Joe Y. Chang,et al.  Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer , 2005, Current oncology reports.

[173]  G. Giaccone,et al.  Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. , 2003, Journal of the National Cancer Institute.

[174]  W. Curran,et al.  Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. , 1995, Journal of the National Cancer Institute.

[175]  R. Tsuchiya,et al.  Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? , 1996, The Journal of thoracic and cardiovascular surgery.

[176]  Randall K Ten Haken,et al.  Physical models and simpler dosimetric descriptors of radiation late toxicity. , 2007, Seminars in radiation oncology.

[177]  V. Rousson,et al.  Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. , 2005, The Annals of thoracic surgery.

[178]  J. Crowley,et al.  Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[179]  S. Singletary,et al.  Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[180]  W. Sze,et al.  Palliative radiotherapy trials for bone metastases: a systematic review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[181]  J. Minna,et al.  Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma , 1999, Oncogene.

[182]  K. Kelly,et al.  Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). , 2006, Clinical lung cancer.

[183]  M. Socinski,et al.  Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[184]  G. Giaccone,et al.  Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[185]  Douglas C McCrory,et al.  Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. , 2003, Chest.

[186]  David E Morris,et al.  The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. , 2005, International journal of radiation oncology, biology, physics.

[187]  R. Hruban,et al.  Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. , 1994, Cancer research.

[188]  G. Luporini,et al.  Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. , 1999, Journal of the National Cancer Institute.

[189]  Srinivasan Vijayakumar,et al.  Development and validation of a standardized method for contouring the brachial plexus: preliminary dosimetric analysis among patients treated with IMRT for head-and-neck cancer. , 2008, International journal of radiation oncology, biology, physics.

[190]  L. Kostakoglu,et al.  18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[191]  Dag Wormanns,et al.  Impact of low-dose CT on lung cancer screening. , 2004, Lung cancer.

[192]  H. Wakelee,et al.  Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in Eastern Cooperative Oncology Group (ECOG) trial E3590. , 2005, Lung cancer.

[193]  D. Weiner,et al.  p185neu expression in human lung adenocarcinomas predicts shortened survival. , 1990, Cancer research.

[194]  G. Bepler,et al.  Lung cancer. Practice organization. , 2003, Chest.

[195]  A Harvey,et al.  Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[196]  R. Ginsberg,et al.  S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results , 2005 .

[197]  Koichi Yamazaki,et al.  Insertion and fixation of fiducial markers for setup and tracking of lung tumors in radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[198]  Takuma Nemoto,et al.  Adrenalectomy for adrenal metastasis from lung carcinoma , 1990, Journal of surgical oncology.

[199]  A R Feinstein,et al.  The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.

[200]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[201]  B. Thompson,et al.  PET, CT, and MRI with Combidex for mediastinal staging in non-small cell lung carcinoma. , 1999, The Annals of thoracic surgery.

[202]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[203]  J. Samet,et al.  Epidemiology of lung cancer. , 1994, Chest.

[204]  M. Jung,et al.  Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. , 1992, Cancer research.

[205]  N. Wald,et al.  Does breathing other people's tobacco smoke cause lung cancer? , 1986, British medical journal.

[206]  P. Rocmans,et al.  Postoperative radiotherapy after pneumonectomy: impact of modern treatment facilities. , 1993, International journal of radiation oncology, biology, physics.

[207]  J. Crowley,et al.  Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[208]  Charles R. Thomas,et al.  Concomitant Weekly Cisplatin and Thoracic Radiotherapy for Pancoast Tumors of the Lung: Pilot Experience of the San Antonio Cancer Institute , 2002, American journal of clinical oncology.

[209]  H. Li,et al.  Predictors of subclinical nodal involvement in clinical stages I and II non-small cell lung cancer: implications in the inoperable and three-dimensional dose-escalation settings. , 1999, International journal of radiation oncology, biology, physics.

[210]  Masao Nakata,et al.  Surgical treatments for multiple primary adenocarcinoma of the lung. , 2004, The Annals of thoracic surgery.

[211]  M. Mehta,et al.  Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[212]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[213]  Y. Ohtsuki,et al.  Caution against blood transfusion from donors seropositive to adult T-cell leukaemia-associated antigens. , 1982, Lancet.

[214]  N. Müller,et al.  T1 lung cancer: prevalence of mediastinal nodal metastases and diagnostic accuracy of CT. , 1993, Radiology.

[215]  L. Rubinstein,et al.  Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[216]  L. Wilson,et al.  Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[217]  J. Warram Preoperative irradiation of cancer of the lung: Final report of a therapeutic trial. A collaborative study , 1975, Cancer.

[218]  A. Bezjak,et al.  Palliative thoracic radiotherapy for lung cancer: a systematic review. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[219]  DoubleTree Hotel Atlanta DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE CENTERS FOR DISEASE CONTROL AND PREVENTION NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL ADVISORY COMMITTEE FOR INJURY PREVENTION AND CONTROL , 2006 .

[220]  S. Steinberg,et al.  ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. , 1991, Cancer research.

[221]  S. Ou,et al.  Prognostic factors for survival of stage I nonsmall cell lung cancer patients , 2007, Cancer.

[222]  H M Kooy,et al.  Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. , 1995, Journal of the National Cancer Institute.

[223]  S. Swedo,et al.  Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea , 2003, Nature Medicine.

[224]  S. Burdett,et al.  Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials , 1998, The Lancet.

[225]  R. Schilsky,et al.  Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[226]  Kirschner Pa Lung cancer; preoperative radiation therapy and surgery. , 1981 .

[227]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[228]  P. Ms,et al.  HYPOPITUITARISM AFTER CHILDBIRTH. , 1965 .

[229]  R. Hoover,et al.  Dietary carotene and vitamin A and risk of lung cancer among white men in New Jersey. , 1984, Journal of the National Cancer Institute.

[230]  M. Fleischhacker,et al.  Cell-free DNA resuscitated for tumor testing , 2008, Nature Medicine.

[231]  V J Lowe,et al.  Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). , 1995, The Journal of thoracic and cardiovascular surgery.

[232]  Cynthia S. Johnson,et al.  Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[233]  Marshall W. Anderson,et al.  A comparison between the localization of lung tumors in uranium miners and in nonminers from 1947 to 1991 , 1996, Cancer.

[234]  A. Dowlati,et al.  Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. , 1996, The European respiratory journal.

[235]  G. Sibley Radiotherapy for patients with medically inoperable stage I nonsmall cell lung carcinoma , 1998, Cancer.

[236]  W F Whimster,et al.  How reliable is the diagnosis of lung cancer using small biopsy specimens? Report of a UKCCCR Lung Cancer Working Party. , 1993, Thorax.

[237]  A. Jilaihawi,et al.  The management of second primary lung cancers. A single centre experience in 15 years. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[238]  O. Auerbach,et al.  Changes in the bronchial epithelium in relation to smoking and cancer of the lung; a report of progress. , 1957, The New England journal of medicine.

[239]  A. Molassiotis,et al.  Complementary and alternative medicine use in lung cancer patients in eight European countries. , 2006, Complementary therapies in clinical practice.

[240]  D. Boffa,et al.  Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors. , 2008, The Journal of thoracic and cardiovascular surgery.

[241]  Zhong Zheng,et al.  DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. , 2007, The New England journal of medicine.

[242]  H. Merte,et al.  Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[243]  Richard Doll,et al.  Mortality in relation to smoking: 22 years' observations on female British doctors. , 1980, British medical journal.

[244]  N J Wald,et al.  The accumulated evidence on lung cancer and environmental tobacco smoke , 1997, BMJ.

[245]  J. Yokota,et al.  Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. , 1988, Oncogene.

[246]  M. Millenson,et al.  A Phase II Study of Concurrent Carboplatin and Paclitaxel and Thoracic Radiotherapy for Completely Resected Stage II and IIIA Non-small Cell Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[247]  Andrew D. Yates,et al.  Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.

[248]  F. Cappuzzo,et al.  EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[249]  E H Moore,et al.  Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. , 1992, Radiology.

[250]  M. Vangel,et al.  Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[251]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[252]  H. Ohmatsu,et al.  Computed tomography screening for lung carcinoma in Japan , 2000, Cancer.

[253]  M. Kirsh,et al.  Mediastinal metastases in bronchogenic carcinoma: influence of postoperative irradiation, cell type, and location. , 1982, The Annals of thoracic surgery.

[254]  J. Crowley,et al.  S9900: Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial , 2007 .

[255]  F. Hirsch,et al.  Chemoprevention of lung cancer: current status and future prospects. , 2003, Lung cancer.

[256]  B. Jeremic,et al.  Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[257]  G. Giaccone,et al.  Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[258]  D. Gandara,et al.  Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[259]  D. Ferrigno,et al.  Cranial computed tomography as a part of the initial staging procedures for patients with non-small-cell lung cancer. , 1994, Chest.

[260]  Y. Nishiwaki,et al.  Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. , 2008, The Lancet. Oncology.

[261]  Elisabeth Brambilla,et al.  Pathology and genetics of tumours of the lung , pleura, thymus and heart , 2004 .

[262]  F. Wells Lung cancer • 10: Delivering a lung cancer service in the 21st century , 2003, Thorax.

[263]  S. Hecht Environmental tobacco smoke and lung cancer: the emerging role of carcinogen biomarkers and molecular epidemiology. , 1994, Journal of the National Cancer Institute.

[264]  P. Harari,et al.  Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results? , 2004, International journal of radiation oncology, biology, physics.

[265]  P. Ellis,et al.  Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[266]  J. Vansteenkiste,et al.  Role of cervical mediastinoscopy in staging of non-small cell lung cancer without enlarged mediastinal lymph nodes on CT scan. , 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[267]  J. Glick,et al.  Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[268]  Hiroki Shirato,et al.  STEREOTACTIC RADIATION THERAPY WORKSHOP Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study , 2007 .

[269]  G. V. von Schulthess,et al.  Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. , 1997, Radiology.

[270]  P. Rubin,et al.  Long‐term observations of the patterns of failure in patients with unresectable non‐oat cell carcinoma of the lung treated with definitive radiotherapy report by the radiation therapy oncology group , 1987, Cancer.

[271]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[272]  L. Stewart,et al.  Postoperative radiotherapy in non-small-cell lung cancer: update of an individual patient data meta-analysis. , 2005, Lung cancer.

[273]  A. Fischman,et al.  Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer. , 2002, International journal of radiation oncology, biology, physics.

[274]  R. T. Ten Haken,et al.  Long-term results of high-dose conformal radiotherapy for patients with medically inoperable T1-3N0 non-small-cell lung cancer: is low incidence of regional failure due to incidental nodal irradiation? , 2006, International journal of radiation oncology, biology, physics.

[275]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[276]  R. Cerfolio,et al.  Survival of patients with unsuspected N2 (stage IIIA) nonsmall-cell lung cancer. , 2008, The Annals of thoracic surgery.

[277]  D. Carbone The biology of lung cancer. , 1997 .

[278]  H. Wichmann,et al.  Risk factors for lung cancer in young adults. , 1998, American journal of epidemiology.

[279]  M. Flentje,et al.  A Little to a Lot or a Lot to a Little? , 2003, Strahlentherapie und Onkologie.

[280]  R. Arriagada,et al.  Small cell lung cancer and prophylactic cranial irradiation (PCI): perhaps the question is not who needs PCI but who wants PCI? , 1997, European journal of cancer.

[281]  A. Bezjak,et al.  Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). , 2002, International journal of radiation oncology, biology, physics.

[282]  O. Auerbach,et al.  Changes in the bronchial epithelium in relation to smoking and cancer of the lung , 1958, CA: a cancer journal for clinicians.

[283]  Tatsuya Fujisaki,et al.  Dose distribution of narrow beam irradiation for small lung tumor. , 2002, International journal of radiation oncology, biology, physics.

[284]  J. Mulshine,et al.  Epithelial-directed drug delivery: influence of formulation and delivery devices. , 2004, Lung cancer.

[285]  E. Lemarié,et al.  French phase III trial of preoperative chemotherapy (PCT) in resectable stage I (except T1N0), II, IIIa non-small cell lung cancer (NSCLC) , 2000 .

[286]  I. Wistuba,et al.  Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis. , 2001, Annals of diagnostic pathology.

[287]  Marcel van Herk,et al.  Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis. , 2006, International Journal of Radiation Oncology, Biology, Physics.

[288]  G. Omenn,et al.  Contribution of environmental fibers to respiratory cancer. , 1986, Environmental health perspectives.

[289]  Joe Y. Chang,et al.  Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. , 2008, International journal of radiation oncology, biology, physics.

[290]  M. Gail,et al.  Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. , 1986, The New England journal of medicine.

[291]  D. Joseph,et al.  A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[292]  E. Vokes Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer. , 2001, The oncologist.

[293]  E. G. Letourneau,et al.  A Combined Analysis of North American Case-Control Studies of Residential Radon and Lung Cancer , 2006, Journal of toxicology and environmental health. Part A.

[294]  M. Suntharalingam,et al.  Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. , 2004, The Annals of thoracic surgery.

[295]  J. Britton,et al.  Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial , 2008, Thorax.

[296]  P. Maguire,et al.  Clinical and dosimetric predictors of radiation-induced esophageal toxicity. , 1999, International journal of radiation oncology, biology, physics.

[297]  P. Laurent-Puig,et al.  Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation , 2006, The American journal of surgical pathology.

[298]  J. Baird The pathways of lymphatic spread of carcinoma of the lung , 1965, The British journal of surgery.

[299]  L. Tanoue,et al.  The noninvasive staging of non-small cell lung cancer: the guidelines. , 2003, Chest.

[300]  D. Niewoehner,et al.  Do molecular markers predict survival in non-small-cell lung cancer? , 1998, American journal of respiratory and critical care medicine.

[301]  C. Perez,et al.  Impact of tumor control on survival in carcinoma of the lung treated with irradiation. , 1986, International journal of radiation oncology, biology, physics.

[302]  M E Burt,et al.  Incidence of local recurrence and second primary tumors in resected stage I lung cancer. , 1995, The Journal of thoracic and cardiovascular surgery.

[303]  G. Scagliotti,et al.  Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[304]  R. Lotan,et al.  Retinoid chemoprevention of aerodigestive cancer: from basic research to the clinic. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[305]  N. Masuda,et al.  Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer. , 2000, Japanese journal of clinical oncology.

[306]  Walter J Curran,et al.  Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[307]  J. M. Lee,et al.  p53 mutations increase resistance to ionizing radiation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[308]  Ahmed H. YoussefAgha,et al.  Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[309]  R. Simon,et al.  Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[310]  M. Gail,et al.  Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[311]  O. Miettinen,et al.  Survival of Patients with Stage I Lung Cancer Detected on CT Screening , 2008 .

[312]  P. Blitzer,et al.  Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication. , 1993, International journal of radiation oncology, biology, physics.

[313]  F. Berrino,et al.  Modifying risk of developing lung cancer by changing habits of cigarette smoking. , 1984, British medical journal.

[314]  T. Demmy,et al.  Is video-assisted thoracic surgery lobectomy better? Quality of life considerations. , 2008, The Annals of thoracic surgery.

[315]  J. Schiller Noninvasive monitoring of tumors. , 2008, The New England journal of medicine.

[316]  Tsuneo Matsumoto,et al.  Bronchogenic carcinoma: incidence of metastases to normal sized lymph nodes. , 1995, Thorax.

[317]  L. Seymour,et al.  Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer. An analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. , 2005, Lung cancer.

[318]  K. Nihei,et al.  High-dose proton beam therapy for Stage I non-small-cell lung cancer. , 2006, International journal of radiation oncology, biology, physics.

[319]  E. Ruffini,et al.  The significance of intrapulmonary metastasis in non-small cell lung cancer: upstaging or downstaging? A re-appraisal for the next TNM staging system. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[320]  R. Makuch,et al.  myc family DNA amplification in small cell lung cancer patients' tumors and corresponding cell lines. , 1988, Cancer research.

[321]  J. Bradley A review of radiation dose escalation trials for non-small cell lung cancer within the Radiation Therapy Oncology Group. , 2005, Seminars in oncology.

[322]  D. Tashkin,et al.  Physiologic characteristics of malignant unilateral main-stem bronchial obstruction. Diagnosis and Nd-YAG laser treatment. , 1988, The American review of respiratory disease.

[323]  T. Guerrero,et al.  2485 : Preliminary Report of Image-Guided Hypofractionated Stereotactic Body Radiotherapy to Treat Patients With Medically Inoperable Stage I or Isolated Peripheral Lung Recurrent Non-Small Cell Lung Cancer , 2006 .

[324]  Bengt Bergman,et al.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.

[325]  P. Nowell,et al.  Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. , 1990, Cancer research.

[326]  T. Dipetrillo,et al.  248 High incidence of isolated brain metastases (CNSMets) following complete response (CR) in advanced non-small cell lung cancer (NSCLC): A new challenge , 1997 .

[327]  H. Choy,et al.  Patterns of practice survey for nonsmall cell lung carcinoma in the U.S. , 2000, Cancer.

[328]  G. Bepler,et al.  Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[329]  M. Sasaki,et al.  A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma , 1996, Annals of nuclear medicine.

[330]  Andreas Kirschbaum,et al.  Frequency of local recurrence following segmentectomy of stage IA non-small cell lung cancer is influenced by segment localisation and width of resection margins--implications for patient selection for segmentectomy. , 2007, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[331]  G. Bepler,et al.  Epidermal growth factor receptor monoclonal antibodies inhibit the growth of lung cancer cell lines. , 1992, Journal of the National Cancer Institute. Monographs.

[332]  E. Shaw,et al.  The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement , 1997, Cancer.

[333]  J. Roth,et al.  Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. , 1998, Lung cancer.

[334]  R. Cerfolio,et al.  Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study. , 2006, The Journal of thoracic and cardiovascular surgery.

[335]  G J Kutcher,et al.  Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[336]  R. Skoracki,et al.  Reconstruction of the chestwall and thorax , 2006, Journal of surgical oncology.

[337]  Alan Cantor,et al.  RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[338]  H. Groen,et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.

[339]  T. Takahashi,et al.  Radiation therapy for stage I-II non-small cell lung cancer in patients aged 75 years and older. , 1996, Japanese journal of clinical oncology.

[340]  T. Weisenburger,et al.  Effects of Postoperative Mediastinal Radiation on Completely Resected Stage 11 and Stage Ill Epidermoid Cancer of the Lung * LCSG 773 , 2007 .

[341]  P. Johnston,et al.  BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. , 2003, Cancer research.

[342]  A. N. Hicks,et al.  The UDP-Glucuronosyltransferase 2B17 Gene Deletion Polymorphism: Sex-Specific Association with Urinary 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol Glucuronidation Phenotype and Risk for Lung Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[343]  N. Laperriere,et al.  Management of single brain metastasis: a practice guideline , 2007, Current oncology.

[344]  M J Hawkins,et al.  Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[345]  S. Borkan,et al.  Transient ischemia or heat stress induces a cytoprotectant protein in rat kidney. , 1991, The American journal of physiology.

[346]  Atul C Mehta,et al.  Evidence-Based Clinical Practice Guidelines Initial Diagnosis of Lung Cancer : ACCP , 2007 .

[347]  A. Gregor,et al.  Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules. , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[348]  S. Adebonojo,et al.  The results of modern surgical therapy for multiple primary lung cancers. , 1997, Chest.

[349]  P. Wingo,et al.  Cancer statistics, 1997 , 1997, CA: a cancer journal for clinicians.

[350]  Ladislav Pecen,et al.  Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. , 2004, Lung cancer.

[351]  J. Padilla,et al.  Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. , 1999, Lung cancer.

[352]  W. Curran,et al.  The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer. , 1990, International journal of radiation oncology, biology, physics.

[353]  E. Vokes,et al.  Non-small-cell lung cancer. Toward the next plateau. , 1994, Chest.

[354]  Giuseppe Lucio Cascini,et al.  Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). , 2007, Lung cancer.

[355]  J. Reed,et al.  Mediastinal staging of non-small-cell lung cancer with positron emission tomography. , 1995, American journal of respiratory and critical care medicine.

[356]  J. V. van Meerbeeck,et al.  Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study , 2007, Thorax.

[357]  E. Gritz Lung cancer: Now, more than ever, a feminist issue , 1993, CA: a cancer journal for clinicians.

[358]  A. Carrato,et al.  Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[359]  M. Kris,et al.  The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[360]  James L Mulshine,et al.  Lung cancer screening. , 2005, The oncologist.

[361]  B. Telfer,et al.  ZD1839 (‘Iressa’), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model , 2002, British Journal of Cancer.

[362]  C. Begg,et al.  EDITORIALS Reflections on the Landmark Studies of -Carotene Supplementation , 2004 .

[363]  L V Rubinstein,et al.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. , 1995, The Annals of thoracic surgery.

[364]  R. Flores,et al.  Video-Assisted Thoracic Surgery (VATS) Lobectomy: the Evidence Base , 2007, JSLS : Journal of the Society of Laparoendoscopic Surgeons.

[365]  R. Arriagada,et al.  Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. , 1994, Lung cancer.

[366]  Johan Nuyts,et al.  Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[367]  R. Tokars,et al.  Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[368]  R. Borland,et al.  The influence of pretreatment optimism on outcome in patients given radical radiotherapy for non-small cell lung cancer , 2000 .

[369]  Y Maruyama,et al.  A randomized trial of surgery in the treatment of single metastases to the brain. , 1990, The New England journal of medicine.

[370]  S. Anthony,et al.  Chemotherapy plus Radiotherapy Compared with Radiotherapy Alone in the Treatment of Locally Advanced, Unresectable, Non-Small-Cell Lung Cancer , 1996, Annals of Internal Medicine.

[371]  Douglas C McCrory,et al.  Noninvasive staging of non-small cell lung cancer: a review of the current evidence. , 2003, Chest.

[372]  R. Livingston,et al.  Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[373]  Carole Fakhry,et al.  Case-control study of human papillomavirus and oropharyngeal cancer. , 2007, The New England journal of medicine.

[374]  B. Freidlin,et al.  Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[375]  M. Nishimura,et al.  Small‐volume image‐guided radiotherapy using hypofractionated, coplanar, and noncoplanar multiple fields for patients with inoperable Stage I nonsmall cell lung carcinomas , 2002, Cancer.

[376]  R. Kratzke,et al.  Video-assisted thoracoscopic surgery is more favorable than thoracotomy for resection of clinical stage I non-small cell lung cancer. , 2007, The Annals of thoracic surgery.

[377]  D. Slaughter,et al.  “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin , 1953, Cancer.

[378]  S. Hecht,et al.  A tobacco-specific lung carcinogen in the urine of men exposed to cigarette smoke. , 1993, The New England journal of medicine.

[379]  T. Berghmans,et al.  Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy. , 2004, Lung cancer.

[380]  S. Ou,et al.  Natural history of stage I non-small cell lung cancer: implications for early detection. , 2007, Chest.

[381]  E. Baldini,et al.  Prospective study of palliative hypofractionated radiotherapy (8.5 Gy x 2) for patients with symptomatic non-small-cell lung cancer. , 2003, International journal of radiation oncology, biology, physics.

[382]  Hiroki Shirato,et al.  Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .

[383]  R. Ramlau,et al.  Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[384]  J. Bergh,et al.  Increased expression of N-myc in human small cell lung cancer biopsies predicts lack of response to chemotherapy and poor prognosis. , 1987, American journal of clinical pathology.

[385]  J. Fraumeni Respiratory carcinogenesis: an epidemiologic appraisal. , 1975, Journal of the National Cancer Institute.

[386]  Maria Werner-Wasik,et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.

[387]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[388]  S. Kaasa,et al.  Polychemotherapy in advanced non small cell lung cancer: a meta-analysis , 1993, The Lancet.

[389]  J. Crowley,et al.  Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[390]  C. Yiannoutsos,et al.  Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01–24/USO-023 , 2007 .

[391]  W. Yin,et al.  Curative radiotherapy of early operable non-small cell lung cancer. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[392]  D. Arber Effect of Prolonged Formalin Fixation on the Immunohistochemical Reactivity of Breast Markers , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[393]  Mehmet Toner,et al.  Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.

[394]  Angelika Hoess,et al.  Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC). , 2003, International journal of radiation oncology, biology, physics.

[395]  L. Seymour,et al.  Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[396]  K. Matsuo,et al.  Role of Adjuvant Chemotherapy in Patients With Resected Non-Small-Cell Lung Cancer: Reappraisal With a Meta-analysis of Randomized Controlled Trials , 2006 .

[397]  Janakiraman Subramanian,et al.  Lung cancer in never smokers: a review. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[398]  G. Omenn,et al.  The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. , 2004, Journal of the National Cancer Institute.

[399]  R. Abrams,et al.  Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[400]  M. Socinski,et al.  Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose‐escalating conformal thoracic radiation therapy in unresectable Stage IIIA/B nonsmall cell lung carcinoma , 2000 .

[401]  J. Roth,et al.  Resection of lung cancer is justified in high-risk patients selected by exercise oxygen consumption. , 1994, The Annals of thoracic surgery.

[402]  N. Ordóñez The Immunohistochemical Diagnosis of Mesothelioma: A Comparative Study of Epithelioid Mesothelioma and Lung Adenocarcinoma , 2003, The American journal of surgical pathology.

[403]  B. Jeremic,et al.  Impact of treatment interruptions due to toxicity on outcome of patients with early stage (I/II) non-small-cell lung cancer (NSCLC) treated with hyperfractionated radiation therapy alone. , 2003, Lung cancer.

[404]  M. Matthews,et al.  Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer. , 1973, Cancer chemotherapy reports. Part 3.

[405]  Indrin J Chetty,et al.  A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[406]  R. Brookmeyer,et al.  Serum beta-carotene, vitamins A and E, selenium, and the risk of lung cancer. , 1986, The New England journal of medicine.

[407]  J. Wisnivesky,et al.  Thoracoscopic lobectomy: report on safety, discharge independence, pain, and chemotherapy tolerance. , 2008, The Journal of thoracic and cardiovascular surgery.

[408]  R. Jaszczak,et al.  Quantification of radiation-induced regional lung injury with perfusion imaging. , 1997, International journal of radiation oncology, biology, physics.

[409]  T. Naruke,et al.  Is major pulmonary resection by video-assisted thoracic surgery an adequate procedure in clinical stage I lung cancer? , 2004, Chest.

[410]  Y. Nishiwaki,et al.  A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[411]  R. Mohan,et al.  Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. , 2006, International journal of radiation oncology, biology, physics.

[412]  J. Ware,et al.  Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. , 1987, The New England journal of medicine.

[413]  G. I. Bell,et al.  Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization. , 1986, Nucleic acids research.

[414]  Douglas C McCrory,et al.  Invasive staging of non-small cell lung cancer: a review of the current evidence. , 2003, Chest.

[415]  Carlo Bartolozzi,et al.  Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). , 2008, The Lancet. Oncology.

[416]  G. Roviaro,et al.  Long-term survival after videothoracoscopic lobectomy for stage I lung cancer. , 2004, Chest.

[417]  M. V. van Herk,et al.  Precise and real-time measurement of 3D tumor motion in lung due to breathing and heartbeat, measured during radiotherapy. , 2002, International journal of radiation oncology, biology, physics.

[418]  A. A. Obrer,et al.  Valor pronóstico de la citología positiva hallada en el lavado pleural de pacientes con cáncer de pulmón. Estudio prospectivo , 1996 .

[419]  D. Ettinger,et al.  Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[420]  Kurt Baier,et al.  Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. , 2002, International journal of radiation oncology, biology, physics.

[421]  V Kalff,et al.  (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[422]  Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. , 2007, Journal of the National Cancer Institute.

[423]  A. Oxman,et al.  Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[424]  J. Smart Can lung cancer be cured by irradiation alone? , 1966, JAMA.

[425]  E. Dmitrovsky,et al.  Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. , 1993, Cancer research.

[426]  M. Melamed,et al.  Lung cancer and exposure to tobacco smoke in the household. , 1990, The New England journal of medicine.

[427]  T. Araki,et al.  Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma , 2004, Cancer.

[428]  P. Rigo,et al.  Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer , 1998, European Journal of Nuclear Medicine.

[429]  R K Ten Haken,et al.  Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. , 1998, International journal of radiation oncology, biology, physics.

[430]  N. Martini,et al.  The role of surgery in N2 lung cancer. , 1987, The Surgical clinics of North America.

[431]  D. Ettinger,et al.  Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. , 1997, International journal of radiation oncology, biology, physics.

[432]  L. Schwartz,et al.  Pulmonary nodules resected at video-assisted thoracoscopic surgery: etiology in 426 patients. , 1999, Radiology.

[433]  R. Arriagada,et al.  Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. , 1992, Journal of the National Cancer Institute.

[434]  M. Socinski,et al.  Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[435]  Y. Mizushima,et al.  Effect of cisplatin exposure on the degree of N-myc amplification in small cell lung carcinoma cell lines with N-myc amplification. , 1996, Oncology.

[436]  E. Lemarié,et al.  Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[437]  F. Cappuzzo,et al.  HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. , 2006, The New England journal of medicine.

[438]  Quynh-Thu Le,et al.  Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. , 2003, The Annals of thoracic surgery.

[439]  Nancy P. Mendenhall,et al.  Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. , 2003 .

[440]  C. Der,et al.  The Ras signal transduction pathway , 1994, Cancer and Metastasis Reviews.

[441]  Tae Hyun Kim,et al.  Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. , 2005, Radiology.

[442]  E. Noordijk,et al.  Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer. , 1988, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[443]  R. Rosell,et al.  Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. , 2008, International journal of radiation oncology, biology, physics.

[444]  William Pao,et al.  Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[445]  L. Lemaitre,et al.  Is computed tomography guided biopsy still necessary for the diagnosis of adrenal masses in patients with resectable non-small-cell lung cancer? , 1999, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[446]  G. Bepler,et al.  ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. , 2005, Chest.

[447]  Lech Papiez,et al.  Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[448]  Thomas Krieger,et al.  Influence of calculation model on dose distribution in stereotactic radiotherapy for pulmonary targets. , 2005, International journal of radiation oncology, biology, physics.

[449]  J. Crowley,et al.  Induction chemotherapy before surgery for early-stage lung cancer: A novel approach. Bimodality Lung Oncology Team. , 2000, The Journal of thoracic and cardiovascular surgery.

[450]  M. Gould,et al.  Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes: ACCP evidenced-based clinical practice guidelines (2nd edition). , 2007, Chest.

[451]  C. Belani,et al.  A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[452]  R. Fisher,et al.  Measurement of lung tumor volumes using three-dimensional computer planning software. , 2002, International journal of radiation oncology, biology, physics.

[453]  Bernard Dubray,et al.  Conformal radiotherapy for lung cancer: different delineation of the gross tumor volume (GTV) by radiologists and radiation oncologists. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[454]  M. Kris,et al.  Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[455]  Takehiko Fujisawa,et al.  Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. , 2006, Chest.

[456]  M. Tockman,et al.  The early detection of second primary lung cancers by sputum immunostaining. LCEWDG Investigators. Lung Cancer Early Detection Group. , 1994, Chest.

[457]  M. Krzakowski,et al.  Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors , 2004, Cancer.

[458]  M. Sporn,et al.  Can dietary beta-carotene materially reduce human cancer rates? , 1981, Nature.

[459]  J. Herndon,et al.  Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[460]  E. Ernst The prevalence of complementary/Alternative medicine in cancer , 1998, Cancer.

[461]  W. Curran,et al.  Phase III comparison of sequential vs concurrent chemoradiation for pts with unresected stage III non-small cell lung cancer (NSCLC): Report of Radiation Therapy Oncology Group (RTOG) 9410 , 2000 .

[462]  T. Hickish,et al.  Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[463]  Richard A Popple,et al.  Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. , 2002, International journal of radiation oncology, biology, physics.

[464]  R. Ginsberg,et al.  Modern thirty-day operative mortality for surgical resections in lung cancer. , 1983, The Journal of thoracic and cardiovascular surgery.

[465]  D. Sugarbaker,et al.  Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[466]  F. Shepherd,et al.  Economic issues in lung cancer: a review. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[467]  M. Spitz,et al.  Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[468]  Yuki Togashi,et al.  EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung Cancers , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[469]  D. Mavroudis,et al.  Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients , 2008, PloS one.

[470]  G. Bepler,et al.  Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients , 2004, Clinical Cancer Research.

[471]  Radhe Mohan,et al.  Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. , 2006, International journal of radiation oncology, biology, physics.

[472]  J. Hainsworth,et al.  Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network. , 2007, Clinical lung cancer.

[473]  H. Pai,et al.  Overexpression of p53 protein does not predict local-regional control or survival in patients with early-stage squamous cell carcinoma of the glottic larynx treated with radiotherapy. , 1998, International journal of radiation oncology, biology, physics.

[474]  Michael R. Green,et al.  Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): Outcomes update of North American Intergroup 0139 (RTOG 9309) , 2005 .

[475]  D. Zander,et al.  Distinction of pulmonary small cell carcinoma from poorly differentiated squamous cell carcinoma: an immunohistochemical approach , 2005, Modern Pathology.

[476]  P. Schil Surgery : therapeutic indications , 2007 .

[477]  C. Mountain,et al.  Staging classification of lung cancer. A critical evaluation. , 2002, Clinics in chest medicine.

[478]  P. Kvale,et al.  Long-term survival following surgical treatment of solitary brain metastasis in non-small cell lung cancer. , 1996, Chest.

[479]  G. Fletcher Clinical dose-response curves of human malignant epithelial tumours. , 1973, The British journal of radiology.

[480]  M. Ranson,et al.  Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma , 2003, Cancer.

[481]  Sadek Nehmeh,et al.  Does registration of PET and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer? , 2005, International journal of radiation oncology, biology, physics.

[482]  James A. Purdy,et al.  3-D Conformal Radiotherapy for Lung Cancer , 1996 .

[483]  S. Lippman,et al.  Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. , 2001, Journal of the National Cancer Institute.

[484]  K. Rosenzweig,et al.  Three-dimensional conformal radiation therapy (3D-CRT) for early-stage non-small-cell lung cancer. , 2001, Clinical lung cancer.

[485]  C. D. Edwards,et al.  Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. , 1995, Cancer research.

[486]  T. Lawrence,et al.  The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. , 2008, Cancer control : journal of the Moffitt Cancer Center.

[487]  T. Therneau,et al.  Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer: A randomized, phase III trial , 1991 .

[488]  R. Mckenna,et al.  New approaches to the minimally invasive treatment of lung cancer , 2005, Current opinion in pulmonary medicine.

[489]  Alona Muzikansky,et al.  Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. , 2007, The oncologist.

[490]  J. Crowley,et al.  Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[491]  M. Parmar,et al.  Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial , 1997, The Lancet.

[492]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[493]  E. Yorke,et al.  High-Dose Radiotherapy for the Treatment of Inoperable Non–Small Cell Lung Cancer , 2007, Cancer journal.

[494]  G. Bepler,et al.  Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1) , 1999, Mammalian Genome.

[495]  I. Vlachonikolis,et al.  Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial , 2001, The Lancet.

[496]  C. Rübe,et al.  Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[497]  Richard J Stephens,et al.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[498]  S. Kudoh,et al.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[499]  D. Girling,et al.  Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial , 2002, BMJ : British Medical Journal.

[500]  Y. Miyagi,et al.  Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. , 2007, American journal of clinical pathology.

[501]  D. Pérol,et al.  Prospective evaluation of early lung toxicity following three-dimensional conformal radiation therapy in non-small-cell lung cancer: preliminary results. , 2000, International journal of radiation oncology, biology, physics.

[502]  Bruce W. Turnbull,et al.  Effects of Selenium Supplementation for Cancer Prevention in Patients With Carcinoma of the Skin: A Randomized Controlled Trial , 1996 .

[503]  M. Socinski,et al.  Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[504]  J. Shrager,et al.  Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[505]  G. Omenn,et al.  Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. , 1996, The New England journal of medicine.

[506]  Thomas Guerrero,et al.  Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[507]  F. Shepherd Treatment of advanced non-small cell lung cancer. , 1994, Seminars in oncology.

[508]  T. Demmy VATS Lobectomy for Frail or Complex Patient , 2003 .

[509]  Jeffrey D Bradley,et al.  Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy. , 2003, International journal of radiation oncology, biology, physics.

[510]  S. Ramalingam,et al.  Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[511]  D. Neuberg,et al.  Outcome for children with group III rhabdomyosarcoma treated with or without radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[512]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[513]  S. Kamholz Pulmonary and cardiovascular consequences of smoking. , 2004, The Medical clinics of North America.

[514]  Jeffrey D Bradley,et al.  Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. , 2002, International journal of radiation oncology, biology, physics.

[515]  D. Poddie,et al.  Long-term results of video-assisted thoracic surgery lobectomy for stage I non-small cell lung cancer: a single-centre study of 104 cases. , 2004, Interactive cardiovascular and thoracic surgery.

[516]  D. Harpole,et al.  Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. , 2007, The Annals of thoracic surgery.

[517]  K. Kelly,et al.  New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[518]  L. Stewart,et al.  A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[519]  S. Monfardini,et al.  Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. , 1992, International journal of radiation oncology, biology, physics.

[520]  F. André,et al.  Patterns of relapse of N2 nonsmall‐cell lung carcinoma patients treated with preoperative chemotherapy , 2001, Cancer.

[521]  E. Gore RTOG 0214: a phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer. , 2005, Clinical advances in hematology & oncology : H&O.

[522]  H. Schirrmeister,et al.  Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[523]  P. Boyle,et al.  Lung cancer and tobacco smoking. , 1995, Lung cancer.

[524]  G. Giaccone,et al.  Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[525]  David Gonzales,et al.  Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial , 2006 .

[526]  J. Bradley,et al.  Radiation pneumonitis and esophagitis in thoracic irradiation. , 2006, Cancer treatment and research.

[527]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[528]  P. Vilmann,et al.  Transesophageal Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA) and Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) Biopsy: a Combined Approach in the Evaluation of Mediastinal Lesions , 2005, Endoscopy.

[529]  N. Mitsuhashi,et al.  High-dose radiation therapy for inoperable non-small cell lung cancer without mediastinal involvement (clinical stage N0, N1). , 1996, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[530]  Radhe Mohan,et al.  Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[531]  Michael K Gould,et al.  Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). , 2007, Chest.

[532]  L B Marks,et al.  The role of three dimensional functional lung imaging in radiation treatment planning: the functional dose-volume histogram. , 1995, International journal of radiation oncology, biology, physics.

[533]  Thomas J. Smith,et al.  American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[534]  M. Socinski,et al.  High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. , 2002, International journal of radiation oncology, biology, physics.

[535]  K. Ang,et al.  In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[536]  M. Mehta,et al.  A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. , 2002, International journal of radiation oncology, biology, physics.

[537]  M. Tang,et al.  Preferential Formation of Benzo[a]pyrene Adducts at Lung Cancer Mutational Hotspots in P53 , 1996, Science.

[538]  E. Vokes Integration of vinorelbine into chemotherapy strategies for non-small-cell lung cancer. , 1995, Oncology.

[539]  C. Mountain The new International Staging System for Lung Cancer. , 1986, The Surgical clinics of North America.

[540]  T. Pajak,et al.  Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. , 1993, International journal of radiation oncology, biology, physics.

[541]  V. Seshan,et al.  Use of video-assisted thoracic surgery for lobectomy in the elderly results in fewer complications. , 2008, The Annals of thoracic surgery.

[542]  H. Groen,et al.  Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[543]  D. Carney Lung cancer--time to move on from chemotherapy. , 2002, The New England journal of medicine.

[544]  G. Colice,et al.  The physiologic evaluation of patients with lung cancer being considered for resectional surgery. , 2003, Chest.

[545]  M. Socinski,et al.  Dose‐escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma , 2001, Cancer.

[546]  R. Peschel,et al.  Results of radical radiation therapy in clinical stage I, technically operable non-small cell lung cancer. , 1987, International journal of radiation oncology, biology, physics.

[547]  Zhongxing Liao,et al.  Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). , 2005, International journal of radiation oncology, biology, physics.

[548]  A. Garden,et al.  Superior sulcus tumors: treatment selection and results for 85 patients without metastasis (Mo) at presentation. , 1990, International journal of radiation oncology, biology, physics.

[549]  A. Neugut,et al.  Differences in histology between first and second primary lung cancer. , 1992, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[550]  H. Wieand Is relative risk reduction a useful measure for patients or families who must choose a method of treatment? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[551]  H. Wada,et al.  Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[552]  R. V. van Klaveren,et al.  Can elective nodal irradiation be omitted in stage III non-small-cell lung cancer? Analysis of recurrences in a phase II study of induction chemotherapy and involved-field radiotherapy. , 2002, International journal of radiation oncology, biology, physics.

[553]  G. Silvestri,et al.  Invasive staging: The guidelines , 2003 .

[554]  M. Mehta,et al.  Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: results of Eastern Cooperative Oncology Group 4593. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[555]  K. Nackaerts,et al.  Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lu , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[556]  K. Roberts,et al.  PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy. , 2005, Lung cancer.

[557]  R. T. Ten Haken,et al.  High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study. , 2005, International journal of radiation oncology, biology, physics.

[558]  M. Boers,et al.  Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial , 2002, The Lancet.

[559]  J. Armstrong Target volume definition for three-dimensional conformal radiation therapy of lung cancer. , 1998, The British journal of radiology.

[560]  J. Roth,et al.  A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. , 1994, Journal of the National Cancer Institute.

[561]  J. Crowley,et al.  Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[562]  R. Clough,et al.  Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. , 2001, International journal of radiation oncology, biology, physics.

[563]  Richard J. K. Taylor,et al.  Meta-analysis of studies of passive smoking and lung cancer: effects of study type and continent. , 2007, International journal of epidemiology.

[564]  V. Gebski,et al.  Radical radiotherapy for early nonsmall cell lung cancer. , 1995, International journal of radiation oncology, biology, physics.

[565]  P. Cornu,et al.  Three irradiation treatment options including radiosurgery for brain metastases from primary lung cancer. , 2003, Lung cancer.

[566]  F. Shepherd,et al.  Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[567]  N. Saijo,et al.  Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[568]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[569]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[570]  N. Ordóñez D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. , 2005, Human pathology.

[571]  Radhe Mohan,et al.  Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. , 2007, International journal of radiation oncology, biology, physics.

[572]  M. Sporn,et al.  Autocrine Secretion—10 Years Later , 1992, Annals of Internal Medicine.

[573]  R. Tsuchiya,et al.  Prognosis and survival in resected lung carcinoma based on the new international staging system. , 1988, The Journal of thoracic and cardiovascular surgery.

[574]  Jinming Yu,et al.  A Randomized Study of Involved-Field Irradiation Versus Elective Nodal Irradiation in Combination With Concurrent Chemotherapy for Inoperable Stage III Nonsmall Cell Lung Cancer , 2007, American journal of clinical oncology.

[575]  Daniel W. Miller,et al.  Hypofractionated proton beam radiotherapy for stage I lung cancer. , 2004, Chest.

[576]  J. Roth,et al.  Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery. , 2003, International journal of radiation oncology, biology, physics.

[577]  D. Libby,et al.  Tumor size predicts survival within stage IA non-small cell lung cancer. , 2003, Chest.

[578]  M. Martel,et al.  Volume and dose parameters for survival of non-small cell lung cancer patients. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[579]  M. Burt,et al.  Resection of brain metastases from non-small-cell lung carcinoma. Results of therapy. Memorial Sloan-Kettering Cancer Center Thoracic Surgical Staff. , 1992, The Journal of thoracic and cardiovascular surgery.

[580]  O S Miettinen,et al.  Early Lung Cancer Action Project , 2001, Cancer.

[581]  J L Pater,et al.  Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[582]  Slobodan Devic,et al.  Impact of FDG-PET/CT on radiotherapy volume delineation in non-small-cell lung cancer and correlation of imaging stage with pathologic findings. , 2008, International journal of radiation oncology, biology, physics.

[583]  P. Blitzer,et al.  Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies. , 1992, International journal of radiation oncology, biology, physics.

[584]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[585]  N. Ordóñez,et al.  Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. , 2000, Advances in anatomic pathology.

[586]  O. Holmberg,et al.  486 The potential impact of 3-D conformal radiotherapy (3DCRT) on continuous hyperfractionated accelerated radiotherapy (CHART) for NSCLC , 1997 .

[587]  K. Mattson,et al.  Docetaxel as neo-adjuvant therapy for radically treatable stage III non-small cell lung cancer: early results of an international phase III study. , 2001, Lung cancer.

[588]  L. Peters Altered fractionation schedules , 1992 .

[589]  Kotaro Kameyama,et al.  Prognostic factors in patients with ipsilateral pulmonary metastasis from non-small cell lung cancer. , 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[590]  R. Ginsberg Editorial: Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell lung carcinomas , 1996 .

[591]  Masahiro Hiraoka,et al.  Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. , 2005, International journal of radiation oncology, biology, physics.

[592]  F. Chierichetti,et al.  Does PET/CT modify the therapeutic approach in medical oncology? , 2008 .

[593]  J. Padilla,et al.  Cell type accuracy of bronchial biopsy specimens in primary lung cancer. , 1996, Chest.

[594]  M Volante,et al.  ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[595]  S. Steinberg,et al.  Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. , 1992, The Annals of thoracic surgery.

[596]  W. Woodward Should directly observed therapy be considered for treatment of HIV? , 1996, JAMA.

[597]  W R Markesbery,et al.  Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. , 1998, JAMA.

[598]  Teruaki Koike,et al.  Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. , 2003, The Journal of thoracic and cardiovascular surgery.

[599]  Lesley Seymour,et al.  Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.

[600]  S. Hecht,et al.  DNA and hemoglobin adducts as markers of metabolic activation of tobacco-specific carcinogens. , 1992, Cancer research.

[601]  M. Sinha,et al.  Clinical aspects of leptin. , 1998, Vitamins and hormones.

[602]  P Chomy,et al.  Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[603]  K. Suemasu,et al.  Radiotherapy in inoperable stage I lung cancer. , 1991, Japanese journal of clinical oncology.

[604]  E. Lemarié,et al.  Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[605]  J. Bonner The role of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma , 1999, Cancer.

[606]  R. Komaki,et al.  Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. , 2008, International journal of radiation oncology, biology, physics.

[607]  W. Yin,et al.  A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial. , 2000, International journal of radiation oncology, biology, physics.

[608]  P. Kosmidis Interim results of a phase III trial. Paclitaxel/carboplatin vs paclitaxel/gemcitabine in advanced non-small-cell lung cancer. , 2000, Oncology.

[609]  F. Rea,et al.  Surgical results for multiple primary lung cancers. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[610]  O. Dalesio,et al.  EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. , 2000, Journal of the National Cancer Institute.

[611]  Deborah Imel Nelson,et al.  The global burden of disease due to occupational carcinogens. , 2005, American journal of industrial medicine.

[612]  Ping Li,et al.  Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. , 2006, International journal of radiation oncology, biology, physics.

[613]  M. Green,et al.  Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[614]  G. Ceresoli,et al.  Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[615]  P. Douglas,et al.  Assessment of coronary heart disease morbidity and mortality after radiation therapy for early breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[616]  John P Griffin,et al.  Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition). , 2007, Chest.

[617]  O. Miettinen,et al.  Early Lung Cancer Action Project: overall design and findings from baseline screening , 1999, The Lancet.

[618]  M. Iannuzzi,et al.  Radiation therapy for the treatment of unresected stage I-II non-small cell lung cancer. , 2005, Chest.

[619]  H. Shirato,et al.  Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. , 2007, International journal of radiation oncology, biology, physics.

[620]  R. Muschel,et al.  Cell cycle checkpoints and apoptosis: potential for improving radiation therapy. , 1997, Vitamins and hormones.

[621]  M. Ewen,et al.  The cell cycle and the retinoblastoma protein family , 1994, Cancer and Metastasis Reviews.

[622]  H. Hansen,et al.  Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[623]  Wei-Ting Hwang,et al.  Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[624]  A. D’Andrilli,et al.  Non-small cell lung cancer with single brain metastasis: the role of surgical treatment. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[625]  Comparison of inverse-planned three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for non-small-cell lung cancer. , 2007, International journal of radiation oncology, biology, physics.

[626]  W. Padberg,et al.  [Intrapulmonary tumor cell dissemination and intraoperative pleural lavage as prognostic factors in bronchial carcinoma]. , 1996, Zentralblatt fur Chirurgie.

[627]  E. Harlow,et al.  The retinoblastoma protein is phosphorylated during specific phases of the cell cycle , 1989, Cell.

[628]  E. Gunel,et al.  Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[629]  R. Ginsberg,et al.  Radiotherapy alone for patients with operable carcinoma of the lung. , 1985, Chest.

[630]  W. Yuh,et al.  Cost-effectiveness of high-contrast-dose MR screening of asymptomatic brain metastasis. , 1995, AJNR. American journal of neuroradiology.

[631]  V. Rusch,et al.  Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. , 2006, The Annals of thoracic surgery.

[632]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[633]  G. Patterson,et al.  Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. , 2006, The Journal of thoracic and cardiovascular surgery.

[634]  R. Arriagada,et al.  Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. , 2001, The Journal of thoracic and cardiovascular surgery.

[635]  Michael J Schell,et al.  Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[636]  R. Weichselbaum,et al.  Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[637]  V. Budach,et al.  Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. , 1999, Journal of Clinical Oncology.

[638]  Z. Petrovich,et al.  Prophylactic cranial irradiation in patients with inoperable carcinoma of the lung. Preliminary report of a cooperative trial , 1977, Cancer.

[639]  M. Tsuboi,et al.  Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib , 2006, Clinical Cancer Research.

[640]  R. Arriagada,et al.  Chemotherapy effect on locally advanced non small cell lung carcinoma: A randomized study on 353 patients , 1990 .

[641]  J. Hainsworth,et al.  Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[642]  R. Ginsberg,et al.  Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[643]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[644]  Tae Hyun Kim,et al.  Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[645]  H. Stich,et al.  REDUCTION WITH VITAMIN A AND BETA-CAROTENE ADMINISTRATION OF PROPORTION OF MICRONUCLEATED BUCCAL MUCOSAL CELLS IN ASIAN BETEL NUT AND TOBACCO CHEWERS , 1984, The Lancet.

[646]  R. Mckenna,et al.  Video-assisted thoracic surgery sleeve lobectomy: a case series. , 2008, The Annals of thoracic surgery.

[647]  T Takahashi,et al.  Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. , 1993, Cancer research.

[648]  M. Krause,et al.  Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[649]  C. Chung,et al.  Evaluation of adjuvant postoperative radiotherapy for lung cancer. , 1982, International journal of radiation oncology, biology, physics.

[650]  T. Chevalier,et al.  Re: Stage IIIA category of non-small-cell lung cancer: a new proposal. , 1994, Journal of the National Cancer Institute.

[651]  G. Stuecklschweiger,et al.  Postoperative radiotherapy in radically resected non-small cell lung cancer. , 1997, Chest.

[652]  W. Cleland,et al.  THE TREATMENT OF CARCINOMA OF THE BRONCHUS: A Clinical Trial to Compare Surgery and Supervoltage Radiotherapy , 1963 .

[653]  V. Lorusso,et al.  Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[654]  V. Lorusso,et al.  Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[655]  K. Kerr,et al.  Pathological assessment of mediastinal lymph nodes in lung cancer: implications for non-invasive mediastinal staging. , 1992, Thorax.

[656]  K. Nackaerts,et al.  Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer - A prospective analysis of 50 cases , 1997 .

[657]  D. Sugarbaker,et al.  Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[658]  P. Rubin,et al.  Patterns of tumor recurrence after definitive irradiation for inoperable non-oat cell carcinoma of the lung. , 1980, International journal of radiation oncology, biology, physics.

[659]  Y. Shibamoto,et al.  Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. , 2001, International journal of radiation oncology, biology, physics.

[660]  S. Rodenhuis,et al.  Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. , 1988, Cancer research.

[661]  J. Ausman,et al.  Surgical approach to lung cancer with solitary cerebral metastasis: twenty-five years' experience. , 1986, The Annals of thoracic surgery.

[662]  R. Doll,et al.  Residential radon and lung cancer--detailed results of a collaborative analysis of individual data on 7148 persons with lung cancer and 14,208 persons without lung cancer from 13 epidemiologic studies in Europe. , 2006, Scandinavian journal of work, environment & health.

[663]  R. Stupp,et al.  Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[664]  Yih-Leong Chang,et al.  Surgical treatment of synchronous multiple primary lung cancers: experience of 92 patients. , 2007, The Journal of thoracic and cardiovascular surgery.

[665]  L. Rubinstein,et al.  Adjuvant chemotherapy with cyclophosphamide, doxorubicin, and cisplatin in patients with completely resected stage I non-small-cell lung cancer. The Lung Cancer Study Group. , 1993, Journal of the National Cancer Institute.

[666]  J. Scannell,et al.  The surgical management of carcinoma of the lung; a study of the cases treated at the Massachusetts General Hospital from 1930 to 1950. , 1950, The Journal of thoracic surgery.

[667]  Yih-Leong Chang,et al.  Significance of extranodal extension of regional lymph nodes in surgically resected non-small cell lung cancer. , 2007, Chest.

[668]  M. Graham,et al.  Radiation therapy alone for stage I non-small cell lung cancer. , 1993, International journal of radiation oncology, biology, physics.

[669]  S. Badve,et al.  Expression of cytokeratin 20 in mucinous bronchioloalveolar carcinoma. , 2002, Human pathology.

[670]  C. Dromer,et al.  Total vertebrectomy for en bloc resection of lung cancer invading the spine. , 1996, The Annals of thoracic surgery.

[671]  G. Laureys,et al.  PP17. An economic comparison of inpatient versus outpatient treatment of febrile neutropenia in a pediatric oncology ward , 1997 .

[672]  N. Pavlidis,et al.  Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group. , 2000, Seminars in Oncology.

[673]  C. Sartor,et al.  Mechanisms of Disease: radiosensitization by epidermal growth factor receptor inhibitors , 2004, Nature Clinical Practice Oncology.

[674]  H. Bartelink,et al.  Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. , 1992, The New England journal of medicine.

[675]  J. Fowler,et al.  Phase I results of RTOG L-0117; a phase I/II dose intensification study using 3DCRT and concurrent chemotherapy for patients with Inoperable NSCLC , 2005 .

[676]  J. Wanders,et al.  Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG) , 1994, British Journal of Cancer.

[677]  A. Dowlati,et al.  Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. , 1996, The European respiratory journal.

[678]  Issam El-Naqa,et al.  Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. , 2004, International journal of radiation oncology, biology, physics.

[679]  J. Izbicki,et al.  Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. , 1993, Cancer research.

[680]  G. Bepler,et al.  RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[681]  L. Marks,et al.  Patterns of failure after resection of non-small-cell lung cancer: implications for postoperative radiation therapy volumes. , 2006, International journal of radiation oncology, biology, physics.

[682]  S. Pyrhönen,et al.  Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[683]  A. Cochran,et al.  Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small-cell lung carcinoma. , 1993, Journal of the National Cancer Institute.

[684]  R. Herbst,et al.  Anti-Vascular Endothelial Growth Factor Monoclonals in Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[685]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[686]  G. Giaccone,et al.  Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[687]  Lawrence B Marks,et al.  Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury. , 2002, International journal of radiation oncology, biology, physics.

[688]  M. Wannenmacher,et al.  The impact of 3-D radiotherapy planning after a pneumonectomy compared to a conventional treatment set-up. , 1995, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[689]  Jan Nyman,et al.  Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries , 2006, Acta oncologica.

[690]  W. Curran,et al.  Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. , 2005, International journal of radiation oncology, biology, physics.

[691]  J. Lebesque,et al.  Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. , 2006, International journal of radiation oncology, biology, physics.

[692]  S. Piantadosi,et al.  Randomized phase 2 evaluation of preoperative radiation therapy and preoperative chemotherapy with mitomycin, vinblastine, and cisplatin in patients with technically unresectable stage IIIA and IIIB non-small cell cancer of the lung. LCSG 881. , 1994, Chest.

[693]  B. Whitson,et al.  Surgery for early-stage non-small cell lung cancer: a systematic review of the video-assisted thoracoscopic surgery versus thoracotomy approaches to lobectomy. , 2008, The Annals of thoracic surgery.

[694]  M. Suntharalingam,et al.  Comparison of three treatment options for single brain metastasis from lung cancer , 2000, International journal of cancer.

[695]  B. Jeremic Incidental irradiation of nodal regions at risk during limited-field radiotherapy (RT) in dose-escalation studies in nonsmall cell lung cancer (NSCLC). Enough to convert no-elective into elective nodal irradiation (ENI)? , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[696]  W. Rom,et al.  Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. , 1995, Journal of the National Cancer Institute.

[697]  G. Scagliotti,et al.  Lung Adjuvant Cisplatin Evaluation (LACE): A pooled analysis of five randomized clinical trials including 4,584 patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[698]  H. Kato,et al.  A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. , 2004, The New England journal of medicine.

[699]  M. Parmar,et al.  Postoperative radiotherapy in non-small-cell lung cancer , 1998, The Lancet.

[700]  D. Brizel,et al.  Randomized phase III trial of radiation±Ethyol® (Amifostine) in patients with head and neck cancer , 1997 .

[701]  J. Wisnivesky,et al.  Video-assisted thoracoscopic lobectomy: state of the art and future directions. , 2008, Annals of Thoracic Surgery.

[702]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[703]  D. Gandara,et al.  Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[704]  S. Ramalingam,et al.  Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. , 2008, The oncologist.

[705]  M. Sporn,et al.  Carcinogenesis and cancer: different perspectives on the same disease. , 1991, Cancer research.

[706]  J. Cooper,et al.  Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. , 1991, International journal of radiation oncology, biology, physics.

[707]  M Buyse,et al.  Adjuvant treatment of stage I lung cancer with high-dose vitamin A. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[708]  W. Travis,et al.  The new World Health Organization classification of lung tumours , 2001, European Respiratory Journal.

[709]  M. Sasaki,et al.  The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography , 1996, European Journal of Nuclear Medicine.

[710]  J. Itami,et al.  Clinical outcomes of single‐fraction stereotactic radiation therapy of lung tumors , 2006, Cancer.

[711]  F. Shepherd,et al.  Comparison of Tirazone (Tirapazamine) and cisplatin vs. etoposide and cisplatin in advanced non-small cell lung cancer (NSCLC): Final results of the international Phase III CATAPULT II Trial , 2000 .

[712]  William W Mayo-Smith,et al.  Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients. , 2007, Radiology.

[713]  Baorui Liu,et al.  ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel , 2008, BMC Cancer.

[714]  R. Cowley,et al.  PREOPERATIVE IRRADIATION IN BRONCHOGENIC CARCINOMA. , 1964, The American journal of roentgenology, radium therapy, and nuclear medicine.

[715]  Derek Y. Chiang,et al.  EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.

[716]  K. Forster,et al.  The relationship between local dose and loss of function for irradiated lung. , 2003, International journal of radiation oncology, biology, physics.

[717]  M. Fukuoka,et al.  294 A randomized phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination with mitomycin (M), vindesine (V), and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC): Preliminary analysis , 1997 .

[718]  A. Rosman,et al.  Prognostic implications of normal (<0.10 ng/ml) and borderline (0.10 to 1.49 ng/ml) troponin elevation levels in critically ill patients without acute coronary syndrome. , 2008, The American journal of cardiology.

[719]  M. Kris,et al.  Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non‐small cell lung cancer , 1994, Journal of surgical oncology.

[720]  J A Purdy,et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.

[721]  J. Lafitte,et al.  A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer , 2000 .

[722]  E. Yorke,et al.  Involved-field radiation therapy for inoperable non small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[723]  M. Suntharalingam,et al.  High-dose radiotherapy in trimodality treatment of Pancoast tumors results in high pathologic complete response rates and excellent long-term survival. , 2005, The Journal of thoracic and cardiovascular surgery.

[724]  S. Rodenhuis,et al.  Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. , 1991, Journal of the National Cancer Institute.

[725]  Tudor Ciuleanu,et al.  Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. , 2006, Lung cancer.

[726]  M. Jiroutek,et al.  Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[727]  S. Reske,et al.  Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET). , 1997, Thorax.

[728]  S. Dacic EGFR Assays in Lung Cancer , 2008, Advances in anatomic pathology.

[729]  R. Makuch,et al.  myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. , 1987, The Journal of clinical investigation.

[730]  A. Gregor,et al.  Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[731]  K. Yamaguchi,et al.  Inhibition of growth of human lung adenocarcinoma cell lines by anti-transforming growth factor-alpha monoclonal antibody. , 1989, Journal of the National Cancer Institute.

[732]  A. Turrisi Brain irradiation and systemic chemotherapy for small-cell lung cancer: dangerous liaisons? , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[733]  L J Peters,et al.  Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. , 1990, The New England journal of medicine.

[734]  Thomas Guerrero,et al.  Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[735]  V. Rusch,et al.  Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). , 2001, The Journal of thoracic and cardiovascular surgery.

[736]  J. Mendelsohn The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. , 1990, Seminars in cancer biology.

[737]  P. Hoskin,et al.  Palliative radiotherapy for non-small-cell lung cancer: which dose? , 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

[738]  R. Stephens,et al.  The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party. , 1996, British Journal of Cancer.

[739]  D. Deheinzelin,et al.  Follow-up in lung cancer: how often and for what purpose? , 1999, Chest.

[740]  D. Grunenwald Surgery for advanced stage lung cancer. , 2000, Seminars in surgical oncology.

[741]  Non-small cell lung cancer with ipsilateral pulmonary metastases: prognosis analysis and staging assessment. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[742]  T. McCain,et al.  Staging by positron emission tomography predicts survival in patients with non-small cell lung cancer. , 2001, Chest.

[743]  S. Adak,et al.  A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern Cooperative Oncology Group. , 2000, The New England journal of medicine.

[744]  D. Ettinger,et al.  Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[745]  K. Propert,et al.  A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. , 1990, The New England journal of medicine.

[746]  Michael R. Green,et al.  236 Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy (INDCT) followed by concomitant chemoradiotherapy (XRT) in stage IIIB non small cell lung cancer (NSCLC): Toxicity data (CALGB study 9431) , 1997 .

[747]  D. Ettinger,et al.  Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01 , 2002 .

[748]  M. Mehta,et al.  Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[749]  E. Vokes CHART for non-small-cell lung cancer-promises and limitations , 1997, The Lancet.

[750]  W. Richards,et al.  Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non‐small cell lung cancer in CALGB protocol #8935 , 2006, Journal of surgical oncology.

[751]  W. Hilgers,et al.  Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[752]  P Schraube,et al.  Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. , 1995, International journal of radiation oncology, biology, physics.

[753]  Hong Wang,et al.  Protein profiles associated with survival in lung adenocarcinoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.